NeoGenomics Inc (NEO)
Return on equity (ROE)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | -78,726 | -77,728 | -78,545 | -84,234 | -87,968 | -96,329 | -114,665 | -125,637 | -144,250 | -163,322 | -146,818 | -35,642 | -8,348 | 48,828 | 71,733 | -10,964 | 4,172 | -4,949 | -5,363 | 3,452 |
| Total stockholders’ equity | US$ in thousands | 902,339 | 908,210 | 915,884 | 923,410 | 941,537 | 947,428 | 956,192 | 974,462 | 998,023 | 1,012,990 | 1,043,520 | 1,075,000 | 1,108,280 | 1,137,240 | 1,148,360 | 843,714 | 694,294 | 666,363 | 654,229 | 505,043 |
| ROE | -8.72% | -8.56% | -8.58% | -9.12% | -9.34% | -10.17% | -11.99% | -12.89% | -14.45% | -16.12% | -14.07% | -3.32% | -0.75% | 4.29% | 6.25% | -1.30% | 0.60% | -0.74% | -0.82% | 0.68% |
December 31, 2024 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-78,726K ÷ $902,339K
= -8.72%
NeoGenomics Inc's return on equity (ROE) has displayed significant fluctuations over the past few years. The ROE was positive in the range of 0.60% to 6.25% between December 2019 and June 2021. However, starting from March 2022, the ROE turned negative and continued to decline steadily, reaching a low of -16.12% by September 2022.
The negative trend in ROE may indicate challenges in generating profits relative to shareholders' equity, suggesting potential issues with the company's profitability and efficiency in utilizing equity to generate returns. Investors and stakeholders may monitor this trend closely to assess NeoGenomics Inc's financial health and management effectiveness in the future.